17 December 2020
|Global media contact:
AJ Vaccines A/S | Denmark
Mr. Christian Malling
M: +45 2552 8170
AJ Vaccines intend to widen activities in the Middle East Region
AJ Vaccines’ production site-facility in Copenhagen, Denmark has been approved by the Gulf Health Council (GHC) effective 9 November 2020. The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region.
In recent years, the regulatory requirements for vaccine registration have become increasingly sophisticated in the GCC countries, namely the Kingdom of Saudi Arabia, the United Arab Emirates, Bahrain, Kuwait, Qatar and Oman. As vaccines are given to large numbers of healthy individuals there is a strong focus upon quality, safety and efficacy in assessing their benefit-risk to public health.
“This GHC registration accentuates AJ Vaccines’ ambitions to further improve access to high-quality, innovative vaccines to serve the global community and for patients to diagnostics and therapeutic solutions. In addition, it is a testimony to the resilience, dedication and professionalism of the entire AJ Vaccines team securing this achievement for our company amid the continued restrictions due to COVID-19”, says Jesper Helmuth Larsen CEO of AJ Vaccines.
Promising growth trajectory
The new GHC registration is in line with AJ Vaccines’ ambition for global growth. “Our employees are aware of the current global challenges and are committed to finding solutions towards a world free of serious diseases across all generations. The GHC registration will leverage our competitiveness and enable us to enter new markets with promising growth trajectories hereby supporting our objective of a stronger regional foothold”, says Jérôme Cabannes, COO of AJ Vaccines.
Strong potential for new business
Currently AJ Vaccines supplies BCG Vaccine and Tuberculin to several countries in the region. “The GHC registration will definitely increase our market shares of both products. In addition, I see a potential to market our booster vaccines, cancer therapy and the new inactivated polio vaccine, Picovax® in the region. This innovative dose-sparing polio vaccine is AJ Vaccines response to the growing global demand for inactivated polio vaccines that are key to the success of the Global Polio Eradication Initiative”, concludes Jérôme Cabannes, COO of AJ Vaccines.